Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

NCT07066657 is registered in ClinicalTrials.gov with ArriVent BioPharma, Inc. as lead sponsor.

NCT NCT07066657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07066657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Lead sponsor
ArriVent BioPharma, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 25, 2025
Completion date
December 31, 2030
Enrollment
572 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastric cancer, locally advanced or metastatic solid tumors, pancreatic cancer